Navigation Links
Lexicon's IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Date:7/28/2011

randomized, placebo-controlled trial in healthy volunteers.  In the multiple ascending dose portion of the study, doses of 250 mg, 500 mg, and 750 mg given three times daily, as well as 1,000 mg given twice daily, were administered over the course of 14 days.  There were eight healthy volunteers (six receiving active compound, two receiving placebo) in each dose group.  Study endpoints included safety and tolerability together with pharmacokinetic and pharmacodynamic parameters consisting of measures of both plasma and urinary 5-HIAA.  Data from the study showed that LX1033 produced a statistically significant decrease in both plasma and urinary 5-HIAA as compared to placebo at all doses tested.  Notably, the plasma measures of 5-HIAA in the recent study were obtained from a simple morning blood draw and correlated with results obtained by the traditional 24-hour urine collection method.

"The favorable safety and tolerability profile for LX1033, together with its local site of action within the gastrointestinal tract and ability to potently reduce serotonin synthesis, make this a very attractive candidate for clinical trials in IBS-d, where the need for new treatments is great," said Dr. Pablo Lapuerta, senior vice president and chief medical officer at Lexicon.  "We look forward to advancing this drug into a Phase 2 trial where we can examine safety and efficacy in IBS-d."

About LX1033

LX1033 is an orally-delivered drug candidate for IBS that inhibits tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin.  LX1033 is designed to act locally in the gastrointestinal (GI) tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain.  

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human diseas
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
2. Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
3. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
4. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
5. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
6. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
7. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
10. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)...  PneumRx, Inc. ( www.pneumrx.com ), a leader in ... enrollment in their RENEW Study, nearly 3 months ahead ... IDE pivotal trial for the PneumRx RePneu Coil System, ... anticipated that the study, which began enrolling subjects in ... end of 2014 to enroll 315 patients.  Instead, enrollment ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
(Date:10/20/2014)... 20, 2014   BioNano Genomics announced today achievement ... to collect human data at 30X depth, sufficient for a ... new capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s ... be showcasing this advancement at the American Society for ...
Breaking Medicine Technology:PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Inc. (NASDAQ: GMPM.PK), a marketing and product formulation company ... to retailers, both in the US and internationally, announced ... collection cycle with a major pharmacy retail chain.  Gamma ... distribution center for delivery to retail outlets in the ...
... 27, 2011 / PRNewswire/ -- Bacterin International Holdings, ... in the development of revolutionary bone graft material and anti-infective ... Russell 3000® Index after the market closed on June 24, ... Index and Russell Global Index. Annual reconstitution of ...
Cached Medicine Technology:Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain 2Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain 3Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes 2Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes 3Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes 4
(Date:10/22/2014)... 2014 Medical Solutions , ... happy to announce that our co-founder and CFO, ... Analysts’ Staffing 100 for 2014. Anderson was also ... influential people in the staffing industry,” in 2013.     ... 13th-largest healthcare staffing company in the U.S., was ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- The United ... arriving from Ebola-affected nations of West Africa land ... them for infection with the virus. In ... Johnson noted that 94 percent of air passengers ... at one of these five airports -- New ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... PUNTA GORDA, Fla., April 25 North ... closed on Cypress,Professional Center, 25097 Olympia Avenue, ... medical office building is located near,Charlotte Regional ... practice. The building is being converted to ...
... in partnership with,others to fight the malaria epidemic, ... treatable, malaria continues to devastate communities in,tropical regions ... World Health Organization (WHO), the malaria epidemic causes,debilitating ... and kills,more than one million people each year ...
... Thoratec,Corporation (Nasdaq: THOR ), a world ... support and restore failing hearts,today announced that it ... quarter of 2008 on Thursday, May 1., ... discuss its financial,results and operating activities to all ...
... funds ... clinic., New guide to low-income dental clinics in the ... teeth, gum,disease, extractions, root canals -- the very words give us ... to regularly visit our,dentists for preventive maintenance., Upper Willamette Valley ...
... helping doctors diagnose and treat lung cancer were ... Conference jointly organized by the European Society for ... the Study of Lung Cancer (IASLC) in Geneva, ... Friday 25th April, 16:30), Israeli researchers from Rosetta ...
... AX Series Delivers MyFluVaccine Portal a Next-generation Server Load ... Balancer Platform for Web Application Delivery, ... today,announced that FFF Enterprises, the nation,s largest distributor of ... Series Advanced Traffic Manager to provide a Web application,delivery ...
Cached Medicine News:Health News:Oaks Development Group Acquires Medical Office Building in Punta Gorda, Florida 2Health News:Global Health Progress Initiative Commemorates World Malaria Day 2Health News:Global Health Progress Initiative Commemorates World Malaria Day 3Health News:Thoratec Schedules First Quarter 2008 Conference Call, Webcast 2Health News:Smiles. Made Fresh Daily 2Health News:New genetic techniques to combat lung cancer 2Health News:FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager 2Health News:FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager 3
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology....
Black multi-pinhole occluder...
6 inch hand held occlcuder with 49 holes...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: